This leads to constitutive activation of KRAS and persistent stimulation of downstream signalling pathways that drive many of the cancer hallmarks such as sustained proliferation, metabolic reprogramming, anti-apoptosis, remodelling of the tumour microenvironment, evasion of the immune response, cell migration and metastasis [27,28]. Here, KRAS is linked to cancer.